Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Nucleosides Nucleotides Nucleic Acids ; 23(8-9): 1517-21, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15571289

ABSTRACT

The in vitro modulating effect of Cyclopentenyl cytosine (CPEC) on the metabolism of gemcitabine was studied in lymphocytic and myeloid leukemic cell-lines. In MOLT-3 cells, that were pretreated with CPEC, the incorporation of 2',2'-difluoro-2'-deoxycytidine triphosphate (dFdCTP) into DNA was significantly increased by 57-99% in comparison with cells that were only treated with gemcitabine. The increased incorporation of dFdCTP into DNA in CPEC pretreated cells was paralleled by an increase in apoptotic and necrotic cells of 17-34%. In HL-60 cells that were preincubated with CPEC, increased concentrations of the mono-/di- and triphosphate form of gemcitabine were observed, as well as an increased incorporation of dFdCTP into DNA (+773%). This increased incorporation was paralleled by a significant increase in apoptosis and necrosis. We conclude that CPEC enhances the incorporation of dFdCTP into DNA and thus increases the cytotoxicity of gemcitabine in lymphocytic and myeloid leukemic cell-lines.


Subject(s)
Cytidine/analogs & derivatives , Cytidine/chemistry , Deoxycytidine/analogs & derivatives , Deoxycytidine/pharmacology , Neoplasms/drug therapy , Antimetabolites, Antineoplastic/pharmacology , Antineoplastic Agents/pharmacology , Apoptosis , Carbon-Nitrogen Ligases/metabolism , Cell Line, Tumor , Cell Separation , Clinical Trials as Topic , DNA/chemistry , DNA/drug effects , Dose-Response Relationship, Drug , Flow Cytometry , HL-60 Cells , Humans , Necrosis , Time Factors , Gemcitabine
2.
Br J Cancer ; 91(3): 425-9, 2004 Aug 02.
Article in English | MEDLINE | ID: mdl-15266331

ABSTRACT

This report describes a single-centre study with temozolomide (TMZ) (200 mg m(-2) day(-1) x 5 per cycle of 28 days) in children with (recurrent) high-grade glioma. Magnetic resonance imaging was performed every two cycles. In all, 20 patients were treated between 1998 and 2001 after the UKCCSG/SFOP TMZ phase II trial. All patients had measurable disease. Totally, 15 patients had a relapse after surgery+/-radiotherapy+/-chemotherapy. Overall, five patients received TMZ after surgery or biopsy, awaiting radiotherapy. There were one clinically malignant grade II glioma, 11 grade III and eight grade IV gliomas. Seven tumours had oligodendroglial features. Mean age at start of TMZ was 12.0 years (range 3-20.5 years). In total, eight patients had >8 cycles (range 3-30). One VGPR (currently in CR after surgery), three PRs (with a PFS of 4, 4 and 11 months, respectively) and one MR (PFS 14 months) were observed. Three out of five responses occurred after >4 courses. The overall response rate was 20%. Median progression-free survival (PFS) was 2.0 months (range 3 weeks-34+ months). PFS rate was 20% after 6 months. Median overall survival (OS) was 10 months. Nine patients showed a clinical improvement. Three patients vomitted shortly after TMZ administration, eight patients (13 cycles) experienced grade III/IV thrombocytopenia, occurring predominantly during the fourth week of the first two cycles. Five patients experienced neutropenia, and three patients febrile neutropenia. TMZ is a well-tolerated ambulatory treatment for children with malignant glial tumours. This drug warrants further study in these highly chemoresistant tumours and should be studied either as upfront therapy or in combination therapy.


Subject(s)
Antineoplastic Agents, Alkylating/therapeutic use , Brain Neoplasms/drug therapy , Dacarbazine/analogs & derivatives , Dacarbazine/therapeutic use , Glioma/drug therapy , Administration, Oral , Adolescent , Adult , Antineoplastic Agents, Alkylating/administration & dosage , Antineoplastic Agents, Alkylating/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Brain Neoplasms/pathology , Brain Neoplasms/radiotherapy , Brain Neoplasms/surgery , Child , Child, Preschool , Combined Modality Therapy , Dacarbazine/administration & dosage , Dacarbazine/adverse effects , Disease Progression , Drug Resistance, Neoplasm , Female , Glioma/pathology , Glioma/radiotherapy , Glioma/surgery , Humans , Male , Temozolomide , Treatment Outcome
3.
Leuk Res ; 25(10): 891-900, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11532523

ABSTRACT

Cyclopentenyl cytosine (CPEC) is a nucleoside-analogue that decreases the concentrations of cytidine triphosphate (CTP) and deoxycytidine triphosphate (dCTP) in leukemic cells by inhibiting the enzyme CTP synthetase, resulting in a decreased synthesis of RNA and DNA. Low concentrations of dCTP facilitate the phosphorylation of 1-beta-D arabinofuranosyl cytosine (araC) and the incorporation of arabinofuranosyl cytosine triphosphate (araCTP) into DNA. Apoptosis and necrosis were analyzed by flow cytometric detection of fluorescence-labeled Annexin V in a human T-lymphoblastic MOLT-3 cell-line after incubations with CPEC and/or araC. CPEC induced apoptosis and necrosis in a concentration- (50-300 nM) and time-dependent (8-16 h) way. The observed necrosis proved to be secondary to apoptosis as the caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD-fmk) completely blocked the CPEC-induced apoptosis and necrosis. Coincubation of various concentrations of CPEC and araC for 16h showed a significant additive effect on the occurrence of apoptosis and (secondary) necrosis. In contrast, a preincubation with 37.5 nM of CPEC for 24 h, which by itself caused only minor apoptosis (4%), followed by a coincubation for 16 h with 62.5 nM of araC (7% of apoptotic cells), showed a synergistic effect on the induction of apoptosis (27%, P<0.001). Growth-inhibition experiments with CPEC and araC under various conditions showed an additive effect on the araC-induced growth-inhibition after 48 h. The results indicate that the cytotoxicity of araC can be increased in T-lymphoblasts by CPEC.


Subject(s)
Antimetabolites, Antineoplastic/pharmacology , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Cytarabine/pharmacology , Cytidine/pharmacology , Leukemia, T-Cell/drug therapy , Tumor Cells, Cultured/drug effects , Annexin A5/metabolism , Cell Division/drug effects , Cytidine/analogs & derivatives , Dose-Response Relationship, Drug , Drug Synergism , Humans , Leukemia, T-Cell/metabolism , Leukemia, T-Cell/pathology , Necrosis
4.
Br J Haematol ; 110(1): 161-9, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10930994

ABSTRACT

Cytidine triphosphate (CTP) synthetase is a key enzyme for the synthesis of cytosine (deoxy)ribonucleotides, catalysing the conversion of uridine triphosphate (UTP) into CTP, and has a high activity in several malignancies. In this preclinical study, the enzyme activity and mRNA expression of the enzyme and (deoxy)ribonucleotide concentrations were analysed in leukaemic cells of 57 children suffering from acute lymphocytic leukaemia (ALL). In addition, in vitro experiments were performed with the CTP synthetase inhibitor cyclopentenyl cytosine (CPEC). A significantly higher activity of CTP synthetase (6.5 +/- 3.9 nmol CTP/mg/h) was detected in ALL cells than in lymphocytes of healthy controls (1.8 +/- 0.9 nmol CTP/mg/h, P < 0.001) that was independent of white blood cell (WBC) count, blast percentage, age, gender or type of ALL. The enzyme activity was not correlated with the CTP synthetase mRNA expression. The activity of CTP synthetase in ALL cells compared with non-malignant CD34+ bone marrow controls (5.6 +/- 2.4 nmol CTP/mg/h) was not statistically different. In vitro treatment of ALL cells with CPEC induced a dose-dependent decrease of the CTP concentration. The lowest concentration of CPEC (0.63 microM) induced a depletion of CTP of 41 +/- 20% and a depletion of dCTP of 27 +/- 21%. The degree of CTP depletion of ALL cells after treatment with CPEC was positively correlated with the activity of CTP synthetase. The inhibition of CTP synthetase in situ was confirmed by flux studies using radiolabelled uridine. From these results, it can be expected that CPEC has a cytostatic effect on lymphoblasts of children with ALL.


Subject(s)
Carbon-Nitrogen Ligases/antagonists & inhibitors , Cytidine/analogs & derivatives , Enzyme Inhibitors/pharmacology , Lymphocytes/enzymology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/enzymology , Adult , Antigens, CD34 , Carbon-Nitrogen Ligases/genetics , Case-Control Studies , Cells, Cultured , Child , Child, Preschool , Cytidine/pharmacology , Dose-Response Relationship, Drug , Female , Hematopoietic Stem Cells/enzymology , Hematopoietic Stem Cells/immunology , Humans , Male , RNA, Messenger/analysis , Ribonucleotides/analysis , Statistics, Nonparametric
5.
Eur J Cancer ; 36(5): 627-35, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10738128

ABSTRACT

Cytidine triphosphate (CTP) synthetase is a key enzyme in the anabolic pathways of cytosine and uracil ribonucleotide metabolism. The enzyme catalyses the conversion of uridine triphosphate (UTP) into CTP, and has a high activity in various malignancies, which has led to the development of inhibitors of CTP synthetase for therapeutic purposes. We studied both CTP synthetase activity and ribonucleotide concentrations in leukaemic cells of 12 children suffering from acute non-lymphocytic leukaemia (ANLL), and performed incubation experiments with cyclopentenyl cytosine (CPEC), a nucleoside analogue that is capable of inhibiting CTP synthetase. The CTP synthetase activity in ANLL cells (5.1+/-2.3 nmol CTP/mg/h) was significantly higher compared with granulocytes of healthy controls (0.6+/-0.4 nmol CTP/mg/h, P=0.0002), but was not different from the CTP synthetase activity in non-malignant CD34+ bone marrow cells (5. 6+/-2.4 nmol CTP/mg/h). Major shifts were observed in the various ribonucleotide concentrations in ANLL cells compared with granulocytes: the absolute amount of ribonucleotides was increased with a substantial rise of the CTP (2.4 versus 0.4 pmol/microg protein, P=0.0007) and UTP (8.7 versus 1.6 pmol/microg protein, P=0. 0007) concentrations in ANLL cells compared with granulocytes. Treatment of ANLL cells in vitro with CPEC induced a major depletion (77% with 2.5 microM of CPEC) in the concentration of CTP, whilst the concentrations of the other ribonucleotides remained unchanged. Therefore, the high activity of CTP synthetase in acute non-lymphocytic leukaemic cells can be inhibited by CPEC, which provides a key to a new approach for the treatment of ANLL.


Subject(s)
Antineoplastic Agents/therapeutic use , Carbon-Nitrogen Ligases/antagonists & inhibitors , Cytidine/analogs & derivatives , Leukemia, Myeloid, Acute/enzymology , Neoplasm Proteins/antagonists & inhibitors , Adolescent , Child , Child, Preschool , Cytidine/therapeutic use , Female , Humans , Leukemia, Myeloid, Acute/drug therapy , Male , Tumor Cells, Cultured
8.
Biol Chem ; 380(1): 41-6, 1999 Jan.
Article in English | MEDLINE | ID: mdl-10064135

ABSTRACT

Cytidine triphosphate (CTP) synthase is one of the key enzymes in pyrimidine nucleotide anabolic pathways. The activity of this enzyme is elevated in various malignancies including acute lymphocytic leukemia (ALL). In this study we investigated the activity of CTP synthase in various human blood cells isolated from healthy volunteers by density centrifugation and elutriation centrifugation. We also investigated the mRNA expression of CTP synthase in lymphocytes and monocytes. The highest activity of CTP synthase was found in thrombocytes (6.48 nmol CTP x mg(-1) x h(-1)), followed by that of monocytes (2.23), lymphocytes (1.69), granulocytes (0.52) and erythrocytes (0.42). The activity of CTP synthase in whole blood samples was at an intermediate level (1.27). The mRNA expression of CTP synthase in monocytes was comparable to that observed in lymphocytes.


Subject(s)
Carbon-Nitrogen Ligases/blood , RNA, Messenger/blood , Blood Platelets/enzymology , Blotting, Northern , Carbon-Nitrogen Ligases/biosynthesis , Enzyme Activation , Erythrocytes/enzymology , Granulocytes/enzymology , Humans , Lymphocytes/enzymology , Monocytes/enzymology , RNA, Messenger/biosynthesis
10.
J Chromatogr B Biomed Sci Appl ; 693(2): 287-95, 1997 Jun 06.
Article in English | MEDLINE | ID: mdl-9210431

ABSTRACT

A non-radiochemical assay procedure for CTP synthetase was developed in which CTP is detected at 280 nm after separation with anion-exchange HPLC. A complete separation of all nucleoside triphosphates was achieved within 11 min and the minimum amount of CTP which could be accurately determined proved to be 5 pmol. Therefore, our assay procedure is ten-fold more sensitive compared to the frequently used radiochemical assays. The assay was linear with time and protein concentration, although at low protein concentration a lag phase was observed. An amount of 2 x 10(6) cells was already sufficient to determine the specific activity of CTP synthetase in HL-60 cells, lymphocytes and in lymphoblasts obtained from pediatric patients suffering from acute lymphoblastic leukemia.


Subject(s)
Carbon-Nitrogen Ligases , Ligases/analysis , Lymphocytes/enzymology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/enzymology , Cells, Cultured , Child , Chromatography, High Pressure Liquid , Chromatography, Ion Exchange , Humans , Sensitivity and Specificity , Tumor Cells, Cultured
11.
Int J Dermatol ; 31(6): 404-9, 1992 Jun.
Article in English | MEDLINE | ID: mdl-1512092

ABSTRACT

Before starting methotrexate therapy for cases of recalcitrant psoriasis, a liver biopsy has been usual in order to exclude cirrhosis and moderate or severe fibrosis, which are contraindications for methotrexate treatment. As mortality and morbidity of liver biopsy are not negligible, and as this invasive procedure is unpleasant for the patient and urges clinical admission, we evaluated the possibility of ruling out severe liver pathology by means of ultrasonography, which we compared to liver biopsy. We made this comparison by means of a decision tree. The advantages of this analysis are the clear definition of the decision problem and its alternatives, and the possibility of calculating the risk of each alternative, thus being able to choose the best diagnostic method. In this study, the results of various research groups are discussed, in which liver biopsy and liver ultrasound were compared. In our decision tree we used some of these results and other assumptions, based on comparable studies. We varied the biopsy mortality and the sensitivity of ultrasound to show the change in the risk of each alternative. Our analysis shows that the differences of expected values between the liver biopsy branch and the ultrasonography branch are relatively small. Therefore, we advise each center, which has at its disposal a specialist in liver ultrasonography, to re-evaluate its guidelines with regard to the detection of severe liver pathology before starting methotrexate for the treatment of psoriasis.


Subject(s)
Decision Support Techniques , Liver/diagnostic imaging , Liver/pathology , Psoriasis/diagnostic imaging , Psoriasis/pathology , Algorithms , Biopsy , Humans , Liver Diseases/diagnosis , Methotrexate/therapeutic use , Psoriasis/drug therapy , Ultrasonography
SELECTION OF CITATIONS
SEARCH DETAIL
...